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Objective: Identify and evaluate current treatment recommendations in
Europe for the care of children with diabetes in view of the European Union
(EU) recommendations for Reference Centers.
Methods: A questionnaire was sent in 2008 to representatives of all EU
countries and Norway, all known to be actively involved in pediatric diabetes
care. Participants were asked whether specific guidelines were recommended
and applied in their countries; when possible, they were invited to forward
their national guidelines. As a second step, we evaluated the guideline mostly
used in relationship to the recommendations of the EU.
Results: Information was obtained from all EU countries (including Scotland
and Norway). National guidelines, as available, were forwarded for review. A
15/29 reported to use the International Society for Pediatric and Adolescent
Diabetes (ISPAD) Clinical Practice Consensus Guidelines (CPCG), whereas
10 reported using national guidelines. These national guidelines were partly
based on and/or compatible with ISPAD guidelines, but in most cases were far
less detailed. The size and presentation differed (web based, booklet, page or
chapter in adult guidelines). In four countries, no specific guidelines were used.
As ISPAD CPCG were used most frequently, its content was evaluated within
the EU Centres of Reference recommendations and minor changes were made
in agreement with the ISPAD editor.
Discussion: Differences between guidelines may influence surveillance and
quality of care in pediatric diabetes within Europe. Although a majority of
countries is using or at least mentioning the ISPAD CPCG, their
implementation as EU standard needs further endorsement. As language
difficulties may hamper its implementation on a wider scale, further
translation of the ISPAD guidelines should be endorsed to render it accessible
to all healthcare professionals. With respect to the content, some changes were
then made in agreement with the editors, adjusting them to the European
context. For European Reference Centers, some further guidance on research
may be included. Once implemented on an EU wide level, benchmarking of
carefully defined robust quality of care and quality of life indicators will allow
us to improve these guidelines on a regular basis ensuring an evidence-based
care for all children with diabetes.
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Increased patient mobility, the request for cross border
healthcare as well as the importance of patient’s
knowledge on quality and safety of the care, demands
careful evaluation of the current situation and existing
structures to care for children with diabetes in the
different European Union (EU) countries. One of the
recommendations to enhance EU wide collaboration
and improve health care is the creation of European
Reference Centres or European Reference Networks
(1, 2). To facilitate further creation of reference centres
for diabetes, a number of criteria were developed, which
should be met by those European reference networks
listed in Table 1 with the goal, of providing health
professionals as well as patients within the EU access
to high level, shared expertise in a given field. Although
for a high level of expertise sufficient number of patients
are requested, they must be able to obtain information
in their own language near to where they live. This
emphasises the need to balance any restriction in centre
numbers to achieve a concentration of expertise against
the need for local delivery of care.
The goal of the SWEET project is to harmonize
care in an effort to optimize outcome in children
and adolescents with diabetes mellitus. Differences
have been identified throughout the EU, in access
to care, the liability field, in the training of healthcare
professionals, identification or recognition of reference
centres and more as reported (3).
Use of a common treatment guideline may
contribute to better harmonization in care.
Table 1. Criteria for a European Reference Centre (1)
• There should be sufficient activity and capacity to
provide relevant services at a sustained level of quality.
• Each centre should be capable of providing expert
advice, diagnosis or confirmation of diagnosis and, to
produce and adhere to good practice guidelines and
to implement outcome measures and quality control.
• Each centre should utilize a multidisciplinary approach.
• Each centre should demonstrate a high level of
expertise and experience, as documented through
publications, grants, or honorific positions as well as
through teaching and training activities.
• There should be a strong contribution to ongoing
research.
• Each center should strive for involvement in
epidemiological surveillance such as registries.
• Close links and collaboration with other expert, national
and international centres, and the capacity to network
should be encouraged and maintained.
• Close links and collaboration with patient associations,
where they exist, should be established and nurtured.
• There should be appropriate arrangements for patient
referrals from other EU countries.
• There should be appropriate capacities for diagnosing,
follow-up and management of patients with evidence of
good outcome where applicable.
To gain more information on current clinical practice
in the different EU countries, we investigated whether
national guidelines were in place or whether EU
wide recognized recommendations could be applicable
which would be in line with the recommended criteria
for centres of reference.
Methods
In 2008, a questionnaire was sent to at least one rep-
resentative of all EU countries, Scotland and Norway.
The contact person was either an ISPAD member or
a person with a specific interest in childhood diabetes.
They were asked whether national pediatric diabetes
guidelines existed and/or what other guidelines would
be applicable in their country. Wherever possible/
available they were invited to send these guidelines to
the study coordinators.
With this information, we evaluated whether these
recommendations covered the criteria for European
Reference Centers.
Results
Information on available pediatric diabetes guidelines
was received from all EU countries together with Nor-
way and Scotland. They are summarized in Table 2.
ISPAD Clinical Practice Consensus Guidelines
(ISPAD-CPCG) are the most frequently mentioned
as reference guideline (in 15/29 countries). These
consensus guidelines have been published after peer
review and are based on an international consensus
among pediatric diabetes healthcare professionals (4).
Some countries have national recommendations for
diabetes, but do not specify guidelines for different age
groups. Four countries do not use specific pediatric
guidelines, whereas 10 countries do report having
national pediatric diabetes guidelines. The pediatric
specific recommendations vary in size (half a page –
book), presentation (paper format, page in a booklet,
referenced papers or online.) and content. Although
their concordance with ISPAD CPCG is frequently
mentioned, most guidelines include less detail in
almost all domains. Treatment targets differ as well,
whether one considers the process of care targets
(frequency of visits, screening for associated illnesses
and complications, education, etc.) or outcome
targets (glycemic targets, HbA1c targets in different
age groups). Finally, very limited information is
available on the implementation of the guidelines
(4–7).
As most countries refer to the ISPAD-CPCG, these
guidelines were used as the basis for the EU recom-
mendations and we analyzed these as a second step
within the European context. Most of the requested
criteria for European Reference Centers mentioned
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Table 2. Identified National Pediatric Diabetes Guidelines
Country Guidelines
Austria Currently in preparation
Belgium No national guidelines ISPAD/ESPE guidelines in some centres, ULB with specific recipe
Bulgaria Small leaflet, mainly ISPAD Guidelines
Cyprus N/A
Czech Republic Web-based national guidelines
Denmark Website based, specific information on DKA, CSII, hypoglycaemia and intercurrent infections
Estonia No national published pediatric guidelines
Finland Defined by the Finnish Diabetes Association, not published
France Clinical Guidelines HAS, very global, AJD, ISPAD
Germany National published guidelines, DDG
Greece No national guidelines, Mainly ISPAD, except for DKA (ADA based)
Hungary No pediatric standard of care guidelines, adult and ISPAD
Italy National general pediatric guidelines, not yet really implemented Health structure Guidelines
Ireland ISPAD , BSPED, ADA
Latvia No pediatric standard of care published
Lithuania ISPAD guidelines
Luxemburg Mainly ISPAD guidelines, except for DKA
Malta Diabetes UK and ADA guidelines
Netherlands Web-based national guidelines currently evaluated by the Dutch Diabetes and Endocrinology group,
based on ISPAD
Poland National Diabetes Guidelines with one chapter on pediatric diabetes
Portugal ISPAD
Romania Mainly ISPAD, no national guidelines
Slovakia ISPAD, Slovak Diabetes Association
Slovenia Mainly ISPAD guidelines
Spain No national pediatric standard of care published
Sweden Published guidelines (book) defined by the Pediatric Society for Endocrinology and Diabetes, Swedish
UK ISPAD, BSPED, NICE
Scotland Partly ISPAD, partly individualised approach
Norway Short clinical guideline, paper version
in Table 1 are covered, although some aspects need
further specification within the EU, especially when
discussing harmonization and mobility of patients and
healthcare professionals.
With respect to the structure of care, the multi-
disciplinary teams are the cornerstone of diabetes
care. In the ISPAD CPCG guidelines, different team
members are identified without specification of profes-
sional qualifications. Within the EU, no harmonized
training curriculum is recognized for the different
healthcare professionals, thus hindering the mobility
of healthcare professionals. This needs to be addressed
at the EU level. In the paper ‘Heterogeneity in the
systems of pediatric diabetes care across the European
Union’ (pages 5–14 of this issue), the staff currently
available in the EU centers is reported, which is
clearly differing between centers. This information was
used to propose recommendations with respect to the
number of health professionals needed per 100 patients
as presented in the guidelines and summarised in
Table 3.
Within the process of care, some simplifications
of the ISPAD CPCG have been proposed for EU
implementation to render supervision easier (8). With
respect to care, a recent report on dyslipidemia has led
Table 3. Recommendations for the multidisciplinary special-
ized pediatric diabetes team members per 100 patients in
the optimal, moderate, and minimal setting (E, 8)
Optimal Moderate Minimal
Per 100 patients
Nurse 1.0 FT 0.6 0.5
Doctor 1.0 0.8 0.5
Dietitians 0.5 0.3 0.3
Social worker 0.2 0.2 0.1 (access to)
Psychologists 0.3 0.2 0.1 (access to)
to a treatment change, which has been proposed as well
for the ISPAD CPCG (9).
Finally, the EU recommendations include a
contribution to epidemiology and research as one of
the relevant tasks of the diabetes units. As the ISPAD
CPCG are clinical guidelines, they provide no further
guidance on research.
Discussion
Development and continuous evaluation of best
practice in diabetes mellitus remains one of the
major objectives in diabetes care, possibly allowing
a delay in and/or prevention of later complications
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(10, 11). Within the EU, equal care for children is
sought for all inhabitants and this may be achieved
through comparable recommendations of care. As
mentioned in Table 1, these recommendations should
include guidance on structure, process, and outcome
of care.
We investigated whether guidelines were available in
the member states and observed that in the majority
of EU countries, the ISPAD CPCG were recognized.
Although large scale evaluation of the implementation
of these guidelines are lacking, a current problem in
applying these guidelines in some countries may be
based on language difficulties. A short version of the
guidelines was prepared within Work Package 2 of the
SWEET study which may serve as a shortened version
of the CPCG. The translation of the ISPAD CPCG
may solve this problem and should be endorsed.
With respect to the European Reference Center
Criteria, some further questions arose when analyzing
the recommendations of the ISPAD CPCG. The
multidisciplinary team is considered to be the backbone
of the care provision. Improved mobility of patients
and healthcare professional would suggest the need
for a core training curriculum for the various team
members.
Currently, there exists no unanimity within the
EU concerning the training received by healthcare
professional with a specialty in diabetes. A common
curriculum is needed because the optimal functioning
of a healthcare team requires clear identification and
definition of the duties of all the participants, with
a clear focus on the child at the centre of care.
Translation in ideal numbers has been discussed and is
summarized in Table 3. As this may vary by country,
depending on local circumstances, we differentiated
the requested staff into optimal, moderate, and
minimal numbers. Long-term benchmarking will allow
further adjustment to obtain best practice and cost-
effective functioning. In addition to the need for
harmony within a family, harmony and consistency
of philosophy within the diabetes team will facilitate
clear identification of therapeutic targets (12). Efficient
communication within the team, as well as good
communication with and within families, has an effect
on outcome and necessitate sufficient attention (13, 14).
Careful observation of chronic complications should
be guaranteed on a regular basis. To facilitate this
follow up, the frequency has been simplified in the EU
centers as compared with ISPAD.
As the ISPAD guidelines focus on clinical care, they
do not include any information on research procedures,
e.g., Good Clinical Practice.
Within the EU, new regulations have established
a system of obligations and rewards around the
development of new medicinal products. This has been
done to improve the information available on drugs
used in the pediatric population and to ensure that
the drugs applicable for the pediatric population are
subject to ethical research of the highest quality (15).
Some guidance on research practices would be relevant
and should be pursued in the next revision.
Within this paper, we have only collected informa-
tion on the available guidelines, and their compatibility
with the requested criteria to improve health care
within the EU.
The second step is the long-term evaluation of
achieved clinical targets, including quality of care and
the quality of life of the patients. Only with benchmark-
ing over time, the optimal guidelines become available
and best practice may become general practice.
Through a continuing registry, including robust
comparable data on process and outcome indicators,
the current approaches and guidelines can be evaluated,
where needed adjusted, updated and tested and in this
way allow continuous improvement of care.
Acknowledgement
The Sweet consortium is acknowledged. This report has been
prepared within the SWEET project, financially supported by
the EU project 2007104.
Conflict of interest
The authors declare no conflict of interest.
References
1. Health & consumer protection directorate-general.
Report on the work of the high Level Group on health
services and medical care in 2008. HLG/2008/5 FINAL.
Health & consumer protection directorate-general.
2. RDTF expert group. Final Report on the ECR. RDTF
expert group
3. Di Iorio CT, Carinci F, Azzopardi J et al. Privacy
impact assessment in the design of transnational public
health information systems: the BIRO project. J Med
Ethics 2009: 35: 753–761.
4. ISPAD. Clinical practice consensus guidelines. Pediatr
Diabetes 2009: Suppl. 12: 1–210.
5. LaLoggiaA. Organization of Paediatric Diabetes Units
in Italy. Acta Biomed 2005: 76 (Suppl. 3): 70–74.
6. Edge JA, Swift PG, Anderson W, Turner B; Youth
and Family Advisory Committee of Diabetes UK.
Diabetes services in the UK: fourth national survey;
are we meeting NSF standards and NICE guidelines?
Arch Dis Child 2005: 90: 1005–1009.
7. Gosden C, Edge JA, Holt RI et al. The fifth UK
paediatric diabetes services survey: meeting guidelines
and recommendations? Arch Dis Child 2010: 95:
837–840.
8. Draft Report: Recommendations for Diabetes Care and
Treatment in Paediatric Centres of Reference in the EU
2009. SWEET Project (www.sweetproject.eu)
9. Maahs DM, Wadwa RP, Bishop F, Daniels SR,
Rewers M, Klingensmith GJ. Dyslipidemia in youth
18 Pediatric Diabetes 2012: 13 (Suppl. 16): 15–19
Diabetes mellitus: treatment recommendations in Europe
with diabetes: to treat or not to treat? J Pediatr 2008:
153: 458–465.
10. Lind M, Oden A, Fahlen M, Eliasson B. The true
value of HbA1c as a predictor of diabetic complications:
simulations of HbA1c variables. PLoS One 2009: 4:
e4412.
11. DCCT Research Group. Effect of intensive diabetes
treatment on the development and progression of
long-term complications in adolescents with insulin-
dependent diabetes mellitus: Diabetes Control and
Complications Trial. Diabetes Control and Compli-
cations Trial Research Group. J Pediatr 1994: 125:
177–188.
12. Swift PGF, Skinner TC, de Beaufort CE et al. Target
setting in intensive insulin management is associated
with better metabolic control: the Hvidoere Childhood
Diabetes Study Group Centre Differences Study 2005.
Pediatr Diabetes 2010: 11: 271–278.
13. Cameron FJ, Skinner TC, de Beaufort CE et al; on
behalf of the Hvidoere Study Group on Childhood
Diabetes. Are family factors universally related to
metabolic outcomes in adolescents with type 1 diabetes?
Diabet Med 2008: 25: 463–468.
14. DAWN Diabetes Attitude, Wishes and Needs. (available
from http://www.dawnstudy.com/).
15. Regulation (EC) No 1901/2006 of the European
parliament and of the council 12 December 2006, on
medicinal products for paediatric use and amending
Regulation (EEC) No 1768/92, Directive 2001/20/EC,
Directive 2001/83/EC and Regulation (EC) No 726/2004
(Text with EEA relevance)
Pediatric Diabetes 2012: 13 (Suppl. 16): 15–19 19
Copyright of Pediatric Diabetes is the property of Wiley-Blackwell and its content may not be copied or
emailed to multiple sites or posted to a listserv without the copyright holder's express written permission.
However, users may print, download, or email articles for individual use.
